1. Bergmann M, Grützmacher P, Kaltwasser JP, Schoeppe W (1988) Iron metabolism under rhEPO therapy in patients on maintenance haemodialysis (RDT). 15th Congress of the European Society for Artificial Organs (ESAO), Prag, 29.6.–1. 7.; Abstract Book, p 64
2. Bommer J, Waldherr R, Wieser PH, Ritz E (1985) Kopräzipitation von Aluminium und Eisen bei Dialysepatienten — mögliche pathogenetische Bedeutung? Nieren- und Hochdruckkrankheiten 14/3 und 4
3. Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Bramsiepe P, Scigalla P (1988) Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a Multicenter trial in patients with end-stage-renal disease. In: Koch KM, Kühn K, Nonnast-Daniel B, Scigalla P (eds) Treatment of Renal Anemia with Recombinant Human Erythropoietin. Karger, Basel. Contrib Nephrol 66: 85–93
4. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C (1987) Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 295: 1017–1020
5. De la Serna F-J, Praga M, Gilsanz F, Rodicio J-L, Ruilope L-M, Alcazar J-M (1988) Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine. Lancet I: 1009–1014